Literature DB >> 28674776

Investigating β-adrenergic-induced cardiac hypertrophy through computational approach: classical and non-classical pathways.

Ali Khalilimeybodi1, Alireza Daneshmehr2, Babak Sharif-Kashani3.   

Abstract

The chronic stimulation of β-adrenergic receptors plays a crucial role in cardiac hypertrophy and its progression to heart failure. In β-adrenergic signaling, in addition to the well-established classical pathway, Gs/AC/cAMP/PKA, activation of non-classical pathways such as Gi/PI3K/Akt/GSK3β and Gi/Ras/Raf/MEK/ERK contribute in cardiac hypertrophy. The signaling network of β-adrenergic-induced hypertrophy is very complex and not fully understood. So, we use a computational approach to investigate the dynamic response and contribution of β-adrenergic mediators in cardiac hypertrophy. The proposed computational model provides insights into the effects of β-adrenergic classical and non-classical pathways on the activity of hypertrophic transcription factors CREB and GATA4. The results illustrate that the model captures the dynamics of the main signaling mediators and reproduces the experimental observations well. The results also show that despite the low portion of β2 receptors out of total cardiac β-adrenergic receptors, their contribution in the activation of hypertrophic mediators and regulation of β-adrenergic-induced hypertrophy is noticeable and variations in β1/β2 receptors ratio greatly affect the ISO-induced hypertrophic response. The model results illustrate that GSK3β deactivation after β-adrenergic receptor stimulation has a major influence on CREB and GATA4 activation and consequent cardiac hypertrophy. Also, it is found through sensitivity analysis that PKB (Akt) activation has both pro-hypertrophic and anti-hypertrophic effects in β-adrenergic signaling.

Entities:  

Keywords:  CREB transcription factor; GATA4 transcription factor; Gi/PI3K/Akt/GSK3β pathway; Gi/Ras/Raf/MEK/ERK pathway; Non-classical pathways; β-Adrenergic signaling

Mesh:

Substances:

Year:  2017        PMID: 28674776     DOI: 10.1007/s12576-017-0557-5

Source DB:  PubMed          Journal:  J Physiol Sci        ISSN: 1880-6546            Impact factor:   2.781


  67 in total

1.  A specific pattern of phosphodiesterases controls the cAMP signals generated by different Gs-coupled receptors in adult rat ventricular myocytes.

Authors:  Francesca Rochais; Aniella Abi-Gerges; Kathleen Horner; Florence Lefebvre; Dermot M F Cooper; Marco Conti; Rodolphe Fischmeister; Grégoire Vandecasteele
Journal:  Circ Res       Date:  2006-03-23       Impact factor: 17.367

2.  Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure.

Authors:  M R Bristow; R Ginsburg; V Umans; M Fowler; W Minobe; R Rasmussen; P Zera; R Menlove; P Shah; S Jamieson
Journal:  Circ Res       Date:  1986-09       Impact factor: 17.367

3.  beta-arrestin-dependent, G protein-independent ERK1/2 activation by the beta2 adrenergic receptor.

Authors:  Sudha K Shenoy; Matthew T Drake; Christopher D Nelson; Daniel A Houtz; Kunhong Xiao; Srinivasan Madabushi; Eric Reiter; Richard T Premont; Olivier Lichtarge; Robert J Lefkowitz
Journal:  J Biol Chem       Date:  2005-11-09       Impact factor: 5.157

4.  Beta-adrenergic signals regulate cardiac differentiation of mouse embryonic stem cells via mitogen-activated protein kinase pathways.

Authors:  Lihui Yan; Zhuqing Jia; Jingjing Cui; Hongtao Yang; Huangtian Yang; Yongzhen Zhang; Chunyan Zhou
Journal:  Dev Growth Differ       Date:  2011-06-29       Impact factor: 2.053

5.  The beta(2)-adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through G(i)-dependent coupling to phosphatidylinositol 3'-kinase.

Authors:  A Chesley; M S Lundberg; T Asai; R P Xiao; S Ohtani; E G Lakatta; M T Crow
Journal:  Circ Res       Date:  2000-12-08       Impact factor: 17.367

6.  Src tyrosine kinase is a novel direct effector of G proteins.

Authors:  Y C Ma; J Huang; S Ali; W Lowry; X Y Huang
Journal:  Cell       Date:  2000-09-01       Impact factor: 41.582

7.  Protein kinase D3 is a pivotal activator of pathological cardiac hypertrophy by selectively increasing the expression of hypertrophic transcription factors.

Authors:  Changlin Li; Jing Li; Xiangyu Cai; Haili Sun; Jinjin Jiao; Ting Bai; Xing Wang Zhou; Xiongwen Chen; Donald L Gill; Xiang D Tang
Journal:  J Biol Chem       Date:  2011-10-04       Impact factor: 5.157

8.  Adrenergic receptor stimulation of the mitogen-activated protein kinase cascade and cardiac hypertrophy.

Authors:  M A Bogoyevitch; M B Andersson; J Gillespie-Brown; A Clerk; P E Glennon; S J Fuller; P H Sugden
Journal:  Biochem J       Date:  1996-02-15       Impact factor: 3.857

Review 9.  Anti-beta(1)-adrenergic receptor antibodies and heart failure: causation, not just correlation.

Authors:  Neil J Freedman; Robert J Lefkowitz
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

Review 10.  What is the role of beta-adrenergic signaling in heart failure?

Authors:  Martin J Lohse; Stefan Engelhardt; Thomas Eschenhagen
Journal:  Circ Res       Date:  2003-11-14       Impact factor: 17.367

View more
  11 in total

Review 1.  Clinical-pathological correlations of BAV and the attendant thoracic aortopathies. Part 2: Pluridisciplinary perspective on their genetic and molecular origins.

Authors:  Ares Pasipoularides
Journal:  J Mol Cell Cardiol       Date:  2019-06-06       Impact factor: 5.000

2.  Cardiac Function in Children and Young Adults Treated with MEK Inhibitors: A Retrospective Cohort Study.

Authors:  Nathan J Robison; Jennifer A Su; Melody J Fang; Jemily Malvar; Jondavid Menteer
Journal:  Pediatr Cardiol       Date:  2022-03-01       Impact factor: 1.838

3.  Clinical value of detecting autoantibodies against β1-, β2,- and α1-adrenergic receptors in carvedilol treatment of patients with heart failure.

Authors:  Dong-Yan Hou; Lin Xu; Zhi-Yong Zhang; Xiao-Rong Xu; Xin Wang; Juan Zhang; Jia-Mei Liu; Hua Wang; Jin Chen; Lin Zhang
Journal:  J Geriatr Cardiol       Date:  2020-06       Impact factor: 3.327

Review 4.  Activation of β2 adrenergic receptor signaling modulates inflammation: a target limiting the progression of kidney diseases.

Authors:  Debra Dorotea; Hunjoo Ha
Journal:  Arch Pharm Res       Date:  2020-11-05       Impact factor: 4.946

5.  The stimulation and inhibition of beta-2 adrenergic receptor on the inflammatory responses of ovary and immune system in the aged laying hens.

Authors:  Ali Hatefi; Ahmad Zare Shahneh; Zarbakht Ansari Pirsaraie; Ali Mohammad Alizadeh; Mohammad Pouya Atashnak; Reza Masoudi; Frederic Pio
Journal:  BMC Vet Res       Date:  2021-05-22       Impact factor: 2.741

6.  Shexiang Tongxin dropping pill protects against isoproterenol-induced myocardial ischemia in vivo and in vitro.

Authors:  Jianyong Qi; Wenjun Pan; Yafang Tan; Jiaru Luo; Dancai Fan; Juan Yu; Jiashin Wu; Minzhou Zhang
Journal:  Oncotarget       Date:  2017-11-14

7.  Wogonin Attenuates Isoprenaline-Induced Myocardial Hypertrophy in Mice by Suppressing the PI3K/Akt Pathway.

Authors:  Weichun Qian; Dongsheng Yu; Jia Zhang; Qiaoyun Hu; Chuanfeng Tang; Peiyu Liu; Peng Ye; Xiaoli Wang; Qiu Lv; Minglong Chen; Liang Sheng
Journal:  Front Pharmacol       Date:  2018-08-13       Impact factor: 5.810

8.  β-arrestin2 regulating β2-adrenergic receptor signaling in hepatic stellate cells contributes to hepatocellular carcinoma progression.

Authors:  Xiu-Qin Li; Wen-Ting Peng; Shan Shan; Jing-Jing Wu; Nan Li; Jia-Jia Du; Jia-Chang Sun; Ting-Ting Chen; Wei Wei; Wu-Yi Sun
Journal:  J Cancer       Date:  2021-10-28       Impact factor: 4.207

Review 9.  Review of applications and challenges of quantitative systems pharmacology modeling and machine learning for heart failure.

Authors:  Limei Cheng; Yuchi Qiu; Brian J Schmidt; Guo-Wei Wei
Journal:  J Pharmacokinet Pharmacodyn       Date:  2021-10-12       Impact factor: 2.745

10.  Calcium Sensing Receptor-Related Pathway Contributes to Cardiac Injury and the Mechanism of Astragaloside IV on Cardioprotection.

Authors:  Meili Lu; Bin Leng; Xin He; Zhen Zhang; Hongxin Wang; Futian Tang
Journal:  Front Pharmacol       Date:  2018-10-11       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.